title: Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
abstract: Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma. Widespread use has been limited for several reasons, including concern that their use may preclude enrollment in subsequent clinical trials due to uncertainty about confounding of results and potential toxicities. This meta-analysis estimated survival following treatment with CW for HGG. A literature search identified relevant studies. Overall survival (OS), median survival, and adverse events (AEs) were summarized. Analysis of variance evaluated effects of treatment (CW vs non-CW) and diagnosis (new vs recurrent) on median survival. The analysis included 62 publications, which reported data for 60 studies (CW: n = 3,162; non-CW: n = 1,736). For newly-diagnosed HGG, 1-year OS was 67 % with CW and 48 % without; 2-year OS was 26 and 15 %, respectively; median survival was 16.4 ± 21.6 months and 13.1 ± 29.9 months, respectively. For recurrent HGG, 1-year OS was 37 % with CW and 34 % without; 2-year OS was 15 and 12 %, respectively; median survival was 9.7 ± 20.9 months and 8.6 ± 22.6 months, respectively. Effects of treatment (longer median survival with CW than without; P = 0.043) and diagnosis (longer median survival for newly-diagnosed HGG than recurrent; P < 0.001) on median survival were significant, with no significant treatment-by-diagnosis interaction (P = 0.620). The most common AE associated with wafer removal was surgical site infection (SSI); the most common AEs for repeat surgery were mass effect, SSI, hydrocephalus, cysts in resection cavity, acute hematoma, wound healing complications, and brain necrosis. These data may be useful in the context of utilizing CW in HGG management, and in designing future clinical trials to allow CW-treated patients to participate in experimental protocols.
authors: Department of Neuro-Oncology, Florida Hospital Cancer Institute, 2501 N. Orange Avenue, Suite 286, Orlando, FL, 32804, USA.
authors: Sajeel A
authors: SA
authors: Chowdhary
authors: Timothy
authors: T
authors: Ryken
authors: Herbert B
authors: HB
authors: Newton
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use*; D003652:Decanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D004343:Drug Implants / Q000009:adverse effects / Q000627:therapeutic use; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D011091:Polyesters / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003652:Decanoic Acids; D004343:Drug Implants; D011091:Polyesters; C574855:carmustine, poliferprosan 20 drug combination; D002330:Carmustine
references: Neuro Oncol. 2012 Apr;14(4):482-90
references: 22319220
references: Cancer. 2006 Oct 15;107(8):1891-7
references: 16986124
references: J Neurosurg. 2008 Dec;109 Suppl:106-17
references: 19123896
references: Br J Neurosurg. 2014 Aug;28(4):488-94
references: 24313309
references: Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275
references: 16482400
references: Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9
references: 9218294
references: Cancer Invest. 2004;22(1):1-9
references: 15069758
references: Neurol Res. 2011 Sep;33(7):759-64
references: 21756557
references: Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221
references: 17999840
references: Clin Neurol Neurosurg. 2012 Nov;114(9):1222-5
references: 22464950
references: Curr Med Res Opin. 2008 Nov;24(11):3239-57
references: 18940042
references: J Clin Neurosci. 2011 Mar;18(3):347-51
references: 21237660
references: J Neurooncol. 2015 Jun;123(2):259-66
references: 25947286
references: Cancer. 2009 Aug 1;115(15):3512-8
references: 19514084
references: Cancer. 2009 Aug 1;115(15):3501-11
references: 19514083
references: Expert Rev Anticancer Ther. 2013 Dec;13(12):1453-61
references: 24236823
references: Neuro Oncol. 2010 Aug;12(8):871-81
references: 20511192
references: Cancer. 2012 Sep 15;118(18):4545-54
references: 22359215
references: Neurosurgery. 1999 Jul;45(1):17-22; discussion 22-3
references: 10414561
references: Tumour Biol. 2013 Dec;34(6):3555-9
references: 23904262
references: Curr Oncol. 2007 Oct;14(5):189-94
references: 17938702
references: J Neurosurg. 2008 Feb;108(2):236-42
references: 18240917
references: J Neurosurg. 2001 Aug;95(2):190-8
references: 11780887
references: Neurosurg Rev. 2010 Oct;33(4):441-9
references: 20706757
references: Br J Neurosurg. 2013 Dec;27(6):772-8
references: 23662801
references: Core Evid. 2012;7:115-30
references: 23118709
references: Surg Neurol Int. 2012;3:137
references: 23230518
references: J Neurooncol. 2013 Jun;113(2):163-74
references: 23535992
references: Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007294
references: 21412902
references: Clin Infect Dis. 2003 Mar 15;36(6):759-65
references: 12627360
references: Neuro Oncol. 2003 Apr;5(2):79-88
references: 12672279
references: Br J Neurosurg. 2012 Dec;26(6):818-22
references: 22715955
references: Ann Oncol. 2010 May;21 Suppl 5:v190-3
references: 20555079
references: Br J Neurosurg. 2011 Aug;25(4):459-69
references: 21344976
references: Neurosurg Clin N Am. 2012 Apr;23(2):289-95, ix
references: 22440872
references: Acta Neurochir (Wien). 2010 Nov;152(11):1923-31
references: 20703889
references: Neurol Med Chir (Tokyo). 2014;54(4):290-301
references: 24739422
references: J Neurosurg. 2009 Mar;110(3):583-8
references: 19046047
references: J Neurosurg. 1991 Mar;74(3):441-6
references: 1993909
references: Ann Surg Oncol. 2013 Jun;20(6):2065-72
references: 23212763
references: Clin Cancer Res. 2009 Feb 1;15(3):1064-8
references: 19188181
references: Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
references: 23095881
references: Ann Surg Oncol. 2010 Jul;17(7):1740-6
references: 20443147
references: Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):749-55
references: 21300471
references: J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56
references: 11504770
references: Acta Neurochir (Wien). 2012 Feb;154(2):211-22; discussion 222
references: 22002506
references: J Neurooncol. 2008 Sep;89(3):339-57
references: 18712284
references: Ann Surg Oncol. 2008 Oct;15(10):2887-93
references: 18636295
references: J Natl Compr Canc Netw. 2022 Dec;20(12):1339-1362
references: 36509072
references: J Neurosurg Sci. 2011 Mar;55(1):1-6
references: 21464805
references: Lancet. 1995 Apr 22;345(8956):1008-12
references: 7723496
references: J Neurosurg. 2013 Apr;118(4):821-9
references: 23350777
references: J Neurooncol. 2011 Nov;105(2):275-80
references: 21505945
references: Expert Opin Pharmacother. 2011 Jun;12(8):1325-1332
references: 21548723
references: Cancer. 2009 Oct 15;115(20):4783-94
references: 19637364
references: Acta Neurochir (Wien). 2012 Aug;154(8):1371-8
references: 22718138
references: J Neurooncol. 2008 Jul;88(3):353-7
references: 18389176
references: Acta Neurochir (Wien). 2014 Feb;156(2):313-23
references: 24287680
references: J Neurooncol. 2004 Feb;66(3):351-60
references: 15015668